Sequoia Sciences was established in 1999 with the goal of uncovering the medical potential of previously inaccessible plant compounds.
Sequoia integrated the most advanced purification and characterization technologies to allow high-throughput screening of compounds produced in quantities too low for traditional extract screening. A partnership with the Missouri Botanical Garden allows us to apply this technology to diverse plants from around the world. Our plant compound libraries are currently being screened by major pharmaceutical and consumer products companies.
Over time these efforts have led to the discovery of dozens of new chemical scaffolds, and two new compounds that Sequoia is developing to treat cancer and bacterial infections. A vaccine developed by Sequoia to treat recurrent urinary tract infections is completing Phase 1 clinical trials.